Physician profile
Rose E Paiva
NPI 1902839475
$10,272.25
in general payments reported to CMS, 2019-2025
59 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $1,333 · 2021: $1,547 · 2022: $1,296 · 2023: $2,116 · 2024: $1,542 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,882 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,881.93 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,703.33 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,284.60 | 2019-2025 | |
| Pfizer INC. | $661.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $649.18 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $584.96 | 2019-2025 | Ozempic |
| Astellas Pharma US INC | $564.56 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.65 | 2021-2024 | Jardiance |
| Edwards Lifesciences Corporation | $361.16 | 2023-2025 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $301.48 | 2020-2025 | Mounjaro, Jardiance, Kisunla |
| Actelion Pharmaceuticals US, INC. | $298.04 | 2019-2024 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $291.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $271.43 | 2021-2023 | Xarelto |
| Abbott Laboratories | $215.30 | 2023-2025 | Eterna, Freestyle Libre 2 |
| Celgene Corporation | $205.71 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $193.69 | 2022-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Paiva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.